KALARIS THERAPEUTICS, INC. Cash and Cash Equivalents
KALARIS THERAPEUTICS, INC. (KLRS) had Cash and Cash Equivalents of $43.17 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2026-08-11
- 2026-06-30: Cash and Cash Equivalents, at Carrying Value $43.17M.
- 2026-03-31: Cash and Cash Equivalents, at Carrying Value $34.43M.
- 2025-12-31: Cash and Cash Equivalents, at Carrying Value $98.05M.
- 2025-09-30: Cash and Cash Equivalents, at Carrying Value $42.39M.
| Period end | Cash and Cash Equivalents, at Carrying Value | Cash and Cash Equivalents, at Carrying Value as first filed |
|---|---|---|
| 2026-06-30 | $43.17M 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $34.43M 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $98.05M 10-Q · filed 2026-08-11 | |
| 2025-09-30 | $42.39M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $88.43M 10-Q · filed 2026-08-11 | |
| 2025-03-31 | $100.97M 10-Q · filed 2026-05-12 | |
| 2024-12-31 | $1.64M 10-K · filed 2026-03-17 | $118.29M 10-K · filed 2025-03-07 |
| 2024-09-30 | $1.91M 10-Q · filed 2025-11-12 | $116.86M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $6.24M 10-Q · filed 2025-08-13 | $104.74M 10-Q · filed 2024-08-09 |
| 2024-03-31 | $5.23M 10-Q · filed 2025-05-14 | $86.04M 10-Q · filed 2024-05-13 |
| 2023-12-31 | $90.12M 10-K · filed 2025-03-07 | |
| 2023-09-30 | $95.63M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $196.95M 10-Q · filed 2024-08-09 | |
| 2023-03-31 | $115.70M 10-Q · filed 2024-05-13 | |
| 2022-12-31 | $106.09M 10-K · filed 2024-03-15 | |
| 2022-09-30 | $123.83M 10-Q · filed 2023-11-02 | |
| 2022-06-30 | $71.09M 10-Q · filed 2023-08-03 | |
| 2022-03-31 | $100.21M 10-Q · filed 2023-05-04 | |
| 2021-12-31 | $201.66M 10-K · filed 2023-02-15 | |
| 2021-09-30 | $243.19M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $225.45M 10-Q · filed 2022-08-04 | |
| 2021-03-31 | $168.65M 10-Q · filed 2022-05-05 | |
| 2020-12-31 | $122.66M 10-K · filed 2022-02-10 | |
| 2020-09-30 | $142.25M 10-Q · filed 2021-11-05 | |
| 2020-06-30 | $78.27M 10-Q · filed 2020-09-02 | |
| 2020-03-31 | $168.60M 10-Q · filed 2021-05-06 | |
| 2019-12-31 | $61.08M 10-K · filed 2021-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |